Status: Recruiting
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 13, 2026Locations: 1
Eligibility criteria
Participant is currently enrolled in a pre-defined Novartis-sponsored study and... [+3]
Participant has been permanently discontinued from opnurasib in the parent proto... [+3]